Overview
Adjunctive Treatment With Doxycycline to Enhance the Durability of Endovascular Aortic Aneurysm Repair
Status:
Completed
Completed
Trial end date:
2006-07-01
2006-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The durability of endovascular aneurysm repair (EVAR) has been limited by development of endoleaks which may be secondary to progressive aortic degeneration by matrix metalloproteases (MMP). Doxycycline is a known inhibitor of the MMP family of enzymes in aneurysms. The investigators propose a randomized, controlled trial of adjuvant doxycycline therapy with EVAR to determine its effects on re-intervention, aneurysm shrinkage and serum markers of aneurysmal degeneration.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Barnes-Jewish Hospital
The Foundation for Barnes-Jewish HospitalTreatments:
Doxycycline
Criteria
Inclusion Criteria:- Presence of an abdominal aortic aneurysm (AAA) with a maximum diameter of > or = 4.5
cm
- Planned aneurysm exclusion with endoluminal stent graft (any brand)
Exclusion Criteria:
- Known malignancy not to include prostate cancer or any history of cancer that has not
had a recurrence in the last 5 years.
- Hypersensitivity to doxycycline or any of its components
- Pregnancy
- Ruptured AAA
- Extension of covered portion of the graft above the renal arteries
- Previous endoluminal aneurysm repair